A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Inclusion Criteria: * Written informed consent; * Newly diagnosed histologically or cytologically confirmed NSCLC excluding squamous NSCLC (mixed cancer types should be classified according to the prevalent cell type); * IIIb or IV stage of NSCLC (TNM classification version 6); * Age ≥ 18 years and age ≤ 75 years (both inclusive); * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2, (not declining within 2 weeks prior to the first dose of investigational product); * Life expectancy - 12 weeks or more from the moment of randomization; * Presence of at least 1 measurable tumour with a size not less than 1 cm (revealed with CT slice thickness not more than 5 mm), as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria (specifically, no ascites, pleural, or pericardial effusions, osteoblastic bone metastases, or carcinomatous lymphangitis of the lung as only lesion; * Patients should be able to follow the Protocol procedures (according to Investigator's assessment); * Patients must implement reliable contraceptive measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of investigational product until 6 months after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization, or patients who are postmenopausal (documented) for the past 2 years. Reliable contraceptive measures include two methods of contraception, including one barrier method Exclusion Criteria: * Squamous NSCLC; * Proven coagulopathy, clinically significant hemorrhage in the past including nasal hemorrhage; * absolute neutrophil count \<1500/mm3; * Platelets \<100 000/mm3; * Hemoglobin \< 90 g/L; * Creatinine level ≥1.5 mg/dL; * Bilirubin level ≥1.5 × upper limit of normal (ULN); * Aspartate-aminotransferase(AST) and alanine-aminotransferase (ALT) levels ≥2.5 × ULN (≥5 × ULN for patients with liver metastases); * Alkaline phosphatase level ≥5 × ULN; * Current therapeutic anticoagulation treatment, aspirin (more than 325 mg/day), nonsteroidal anti-inflammatory drugs, antiplatelet agents or protracted treatment with these drugs less than 1 month before entering the study; * Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medical correction methods (low salt diet, physical exercise); * Any previous anticancer therapy (chemotherapy, radiation therapy , surgery etc.) of metastatic NSCLC; * Radiation or hormone therapy within 21 days prior to randomization; * Major surgery 28 days before inclusion into the study; * Previous antiangiogenic therapy; * Hypersensitivity to taxanes, platinum agents, recombinant murine proteins, contrast agents, premedication agents specified by Protocol (dexamethasone, diphenhydramine, ranitidine) or excipients of investigational products; * NSCLC metastases in central nervous system excluding metastases non-progressing without glucocorticosteroids within 4 weeks before inclusion into the trial; * Cardiovascular system pathology (CHF stage III-IV according to New York Heart Association (NYHA) classification); * Pregnancy or lactation; * Conditions limiting patient's adherence to Protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others); * Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0; * Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial; * Any other concomitant cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma; * Acute or active chronic infections; * Hepatitis C virus, hepatitis B virus, HIV, or syphilis infections; * Obstacles in intravenous administration of study drugs